New triple therapy targets tough colorectal cancer mutation

NCT ID NCT06412198

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 34 times

Summary

This study is for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C and has not responded to at least one prior treatment. The trial tests a combination of three drugs (adagrasib, cetuximab, and cemiplimab) to see if they can help control the cancer. About 31 participants will be enrolled to check safety and how well the treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Massachusetts General Hospital Cancer Center

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.